Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304462 | 0.85 | KDM4E (0.48) | NPSR1ALDH1A1GFERHTTKDM6B | |
| SCHEMBL17038775 | 0.84 | L3MBTL1 (0.46) | ALDH1A1HTTKDM6BKDM4AKDM5A | |
| SCHEMBL19487325 | 0.79 | NAALAD2 (0.43) | ALDH1A1KDM6BKDM4AKDM5ATDP1 | |
| SCHEMBL22380609 | 0.78 | KDM6B (0.39) | NPSR1ALDH1A1GFERHTTKDM6B | |
| SCHEMBL17976838 | 0.77 | TDP1 (0.54) | NPSR1ALDH1A1GFERHTTTDP1 | |
| SCHEMBL23828916 | 0.77 | EPHX2 (0.54) | NPSR1ALDH1A1GFERTDP1EPHX2 | |
| SCHEMBL953399 | 0.76 | NAALAD2 (0.67) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL953397 | 0.76 | NAALAD2 (0.67) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL5840984 | 0.74 | KDM6B (0.50) | ALDH1A1HTTKDM6BKDM4AKDM5A | |
| SCHEMBL5840981 | 0.74 | NAALAD2 (0.50) | ALDH1A1HTTKDM6BKDM4AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732103-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-8268822-B2 | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7998990-B2 | 5-phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2011-08-16 | — | — | US | disclosed |
| US-20110071134-A1 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRIMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-7732444-B2 | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| EP-2123647-A1 | 2-(amino-substituted)-4-phenyl pyrimidines useful for treating inflammatory diseases | Millennium Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-1701944-B1 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARM INC (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2029562-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007134827-A1 | 5-PHENYL-THIAZ0L-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| EP-1701944-A2 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005066139-A2 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRAMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071134-A1 | 2-(AMINO-SUBSTITUTED)-4-ARYL PYRIMIDINES AND RELATED COMPOUNDS USEFUL FOR TREATING INFLAMMATORY DISEASES | PRKCZ, PRKCQ, PRKCE | NPSR1 2281/4885ALDH1A1 4044/4885GFER 4832/4885 |
| US-20060040968-A1 | 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases | PRKCZ, PRKCQ, PRKCE | NPSR1 2281/4885ALDH1A1 4044/4885GFER 4832/4885 |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | CNKSR1, CDK8, MAPK8 | NPSR1 1610/4885ALDH1A1 4033/4885GFER 2684/4885 |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | CFD, C9, CFH | NPSR1 4158/4885ALDH1A1 2381/4885GFER 1681/4885 |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, CFH | NPSR1 4158/4885ALDH1A1 2381/4885GFER 1681/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | NPSR1 4158/4885ALDH1A1 2381/4885GFER 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.